Nikhil Singh
@nikhil-singh.bsky.social
ID/AMS Pharmacist 💊 | @NCICancer.bsky.social @Petermaccc.bsky.social
Reposted by Nikhil Singh
Happy Infectious Diseases Pharmacists Day to my colleagues, mentors, and clinician-researcher heroes #IDPharmacistsDay #SIDPAdvocacy @adphaau.bsky.social @sidpharm.bsky.social @ncicancer.bsky.social
May 21, 2025 at 11:48 PM
Happy Infectious Diseases Pharmacists Day to my colleagues, mentors, and clinician-researcher heroes #IDPharmacistsDay #SIDPAdvocacy @adphaau.bsky.social @sidpharm.bsky.social @ncicancer.bsky.social
Reposted by Nikhil Singh
From @cmijournal.bsky.social:
Which trial do we need? Ampicillin versus ampicillin plus ceftriaxone for E. faecalis endocarditis
Would love to see this trial happen!
#IDSky
www.clinicalmicrobiologyandinfection.com/article/S119...
Which trial do we need? Ampicillin versus ampicillin plus ceftriaxone for E. faecalis endocarditis
Would love to see this trial happen!
#IDSky
www.clinicalmicrobiologyandinfection.com/article/S119...
Which trial do we need? Ampicillin versus ampicillin plus ceftriaxone for E. faecalis endocarditis: is it time to start re-considering monotherapy?
Reviewing the evidence behind some established practices in infectious diseases is
both a professional responsibility and an ethical duty of the scientific community.
Combination therapy for Enterococ...
www.clinicalmicrobiologyandinfection.com
April 4, 2025 at 4:48 AM
From @cmijournal.bsky.social:
Which trial do we need? Ampicillin versus ampicillin plus ceftriaxone for E. faecalis endocarditis
Would love to see this trial happen!
#IDSky
www.clinicalmicrobiologyandinfection.com/article/S119...
Which trial do we need? Ampicillin versus ampicillin plus ceftriaxone for E. faecalis endocarditis
Would love to see this trial happen!
#IDSky
www.clinicalmicrobiologyandinfection.com/article/S119...
Reposted by Nikhil Singh
Feels right that my 1st post here should be to share this incredible RCT, led by my PhD supervisor Nick Daneman:
www.nejm.org/doi/full/10....
Main takeaway: 7-days of abx should be the standard of care for patients with uncomplicated non-S. aureus BSI.
A deep dive 🧵:
#IDsky
www.nejm.org/doi/full/10....
Main takeaway: 7-days of abx should be the standard of care for patients with uncomplicated non-S. aureus BSI.
A deep dive 🧵:
#IDsky
Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections | NEJM
Bloodstream infections are associated with substantial morbidity and mortality. Early, appropriate antibiotic therapy is important, but the duration of treatment is uncertain. In a multicenter, non...
www.nejm.org
November 21, 2024 at 6:56 AM
Feels right that my 1st post here should be to share this incredible RCT, led by my PhD supervisor Nick Daneman:
www.nejm.org/doi/full/10....
Main takeaway: 7-days of abx should be the standard of care for patients with uncomplicated non-S. aureus BSI.
A deep dive 🧵:
#IDsky
www.nejm.org/doi/full/10....
Main takeaway: 7-days of abx should be the standard of care for patients with uncomplicated non-S. aureus BSI.
A deep dive 🧵:
#IDsky